Published in Cancer Weekly, February 8th, 2005
Specifically, DOCRO has submitted data showing that by using DR-70 in conjunction with the CEA test, which is the standard test for this disease, there is a 24% positive gain in positive concordance in monitoring the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.